Evidence still lacking for Ebola treatments, concludes European Medicines Agency Lack of evidence for seven investigational drugs being developed for the treatment of Ebola means it is impossible to make conclusions about their safety or efficacy.…
Government advisory board members concerned about removal of anonymity for error reportsCommunity pharmacists in England may face an increased risk of prosecution for a dispensing error because of changes made to their national contract, according to some members of a government advisory board.…
GlaxoSmithKline revises colour and labelling of Relvar Ellipta inhaler GlaxoSmithKline is changing the colour of its Relvar Ellipta inhaler from blue to yellow after respiratory health professionals warned that patients could be confused.…
Survey suggests US doctors are changing their prescribing habits for opioid drugsMany primary care physicians are less likely to prescribe opioids now than a year ago, according to a survey of US doctors.…
Q&A: Pharmacy regulation and the law Lawyer Noel Wardle, a partner at Charles Russell Speechlys, which specialises in business law, talks about UK pharmacy regulation and the threat of pharmacists facing prosecution for dispensing errors.…
Initial Fluad investigations find no manufacturing defectPreliminary investigations have found no manufacturing defect in the influenza vaccine Fluad, which has been linked to the deaths of 13 older people in Italy.…
NHS England issues naloxone warningInappropriate use of naloxone can cause patients severe distress and can be fatal, says NHS England in a Patient Safety Alert.…
EllaOne to be available without prescriptionEllaOne (ulipristal acetate), an emergency contraceptive, is to be made available without a prescription from community pharmacies throughout the European Union.…
WHO joins drive to make all clinical trial data publicly available The World Health Organization has issued an official statement to encourage pharmaceutical companies to publicly disclose clinical trial results.…
Selective COX-2 inhibitors linked to worse outcomes after ischaemic stroke New research suggests that selective cyclooxygenase-2 inhibitors herald worse outcomes following ischaemic stroke.…
